Trial Profile
Role of C-reactive protein for prediction of survival in patients with advanced non-small cell lung cancer treated with first line pembrolizumab monotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 22 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology